首页/化合物/医药原料药/(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one

C₃₇H₆₈N₂O₁₃

748.9 g/mol

医药原料药

(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one

CAS111321-02-9EC978-456-3

用途分类

医药原料药

化合物类别

天然产物

主要用途

医药原料

罗红霉素是一种半合成大环内酯类抗生素前体，衍生自红霉素。它与红霉素具有相同的14元内酯环结构，并在大环内酯环上连接有肟基侧链。

用于大环内酯类抗生素生产的制药原料用于抗菌研究的化合物

内容范围: 本页信息面向化学品识别与工业供应、研发、生产场景，不构成疗效宣称、医疗建议或药品使用指导。

正在采购或供应此化合物？

发布库存产品或采购需求

CAS 111321-02-9

安全参考

环境危害

H411Toxic to aquatic life with long lasting effects

标识符

IUPAC 名称

(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one

InChIKey

KYTWXIARANQMCA-ZTILBQITSA-N

SMILES

CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/O)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O

别名列表 (10)

Clarithromycin EP Impurity J; Roxithromycin EP Impurity C; Azithromycin Impurity S(Erythromycin A 9-Oxime (E-Isomer))
9(E)-Erythromycin A oxime
Erythromycin A-E-Oxime
Erythromycin Impurity J
Erythromycin, 9-oxime
Roxithromycin Impurity C

(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one

相关化合物

安全参考